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IMPORTANCE Despite considerable improvements in heart failure care, mortality rates among
patients in high-income countries have changed little since the early 2000s. Understanding
the reasons underlying these trends may provide valuable clues for developingmore targeted
therapies and public health strategies.
OBJECTIVE To investigate mortality rates following a new diagnosis of heart failure and
examine changes over time and by cause of death and important patient features.
DESIGN, SETTING, AND PARTICIPANTS This population-based retrospective cohort study
analyzed anonymized electronic health records of individuals who received a new diagnosis
of heart failure between January 2002 and December 2013 whowere followed up until
December 2014 from the Clinical Practice Research Datalink, which links information from
primary care, secondary care, and the national death registry from a subset of the UK
population. The data were analyzed from January 2018 to February 2019.
MAIN OUTCOMES ANDMEASURES All-cause and cause-specific mortality rates at 1 year
following diagnosis. Poisson regressionmodels were used to calculate rate ratios (RRs) and
95% confidence intervals comparing 2013 with 2002, adjusting for age, sex, region,
socioeconomic status, and 17 major comorbidities.
RESULTS Of 86833 participants, 42 581 (49%) were women, 51 215 (88%) were white, and
themean (SD) age was 76.6 (12.6) years. While all-cause mortality rates declined only
modestly over time (RR comparing 2013 with 2002, 0.94; 95% CI, 0.88-1.00), underlying
patterns presented explicit trends. A decline in cardiovascular mortality (RR, 0.73; 95% CI,
0.67-0.80) was offset by an increase in noncardiovascular deaths (RR, 1.22; 95% CI, 1.11-1.33).
Subgroup analyses further showed that overall mortality rates declined among patients
younger than 80 years (RR, 0.79; 95% CI, 0.71-0.88) but not among those older than 80
years (RR, 0.97; 95% CI, 0.90-1.06). After cardiovascular causes (898 [43%]), the major
causes of death in 2013 were neoplasms (311 [15%]), respiratory conditions (243 [12%]),
and infections (13%), the latter 2 explaining most of the observed increase in
noncardiovascular mortality.
CONCLUSIONS AND RELEVANCE Among patients with a new heart failure diagnosis,
considerable progress has been achieved in reducingmortality in young andmiddle-aged
patients and cardiovascular mortality across all age groups. Improvements to overall mortality
are hindered by high and increasing rates of noncardiovascular events. These findings
challenge current research priorities andmanagement strategies and call for a greater
emphasis on associated comorbidities. Specifically, infection prevention presents as
a major opportunity to improve prognosis.
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T hepast25yearshavebroughtconsiderableimprovementsinheart failurecare.Newtreatments, suchasβ-blockers,1mineralocorticoid receptor antagonists,2 ivabradine,3
andsacubitril/valsartan,4anddevicetherapies, suchas implant-
able cardioverter defibrillators5 and cardiac resynchronization
therapy,6havebeenintroduced.Multidisciplinarymanagement
teams, includingspecialistnurses,havealsobeendeveloped to
improve thedeliveryof care.7,8Randomizedclinical trialshave
demonstrated theeffectivenessof these treatments in reducing
mortality andhospitalizations, andobservational studieshave
shown that they are increasingly being used worldwide.9-11
Despitethis,severalrecentstudieshavereportedthatthedecline
inmortalityratesamongpatientswithheartfailurehasbeenstall-
ing since the mid-2000s.12-14 To our knowledge, the reasons
underlying this apparent paradox are unknown.
Most studies that have investigated outcomes following
incidentheart failurehave restrictedanalyses toall-causemor-
tality without investigating underlying patterns, such as
changes by subgroup or cause-specific mortality (eTable 1 in
the Supplement). In addition, information about trends in
cause-specific hospitalization rates, which are highly impor-
tant to patients and clinicians, remain poorly investigated.
In-depth analyses investigating how specific causes of mor-
bidity and mortality and changes in patient characteristics
contribute to overall trends would complement these efforts
andmay provide valuable clues for the development ofmore
targeted therapies or public health strategies.
To address these knowledge gaps, we used a database of
electronic health records that links information fromprimary
care, secondary care, and thenational death registry for a rep-
resentative sample of the UKpopulation.We performed a de-
tailed assessment of health outcomes in patients with a new
diagnosisofheart failureandanalyzedchanges incause-specific
mortality and morbidity over time and by important patient
characteristics, such as age, sex, and socioeconomic status.
Methods
Data Source
We used electronic health records from the Clinical Practice
ResearchDatalink (CPRD) fromJanuary 1, 1985, to September
30,2015.TheCPRDdatabasecontainsanonymizedpatientdata
from approximately 7% of the current UK population and is
broadly representative in termsofage, sex,andrace/ethnicity.15
TheCPRD is oneof the largest databases of longitudinalmedi-
cal records in theworld and has been validated for epidemio-
logical research for a range of conditions.15 Primary care rec-
ordswere linkedtohospitaladmissionsusingHospitalEpisodes
Statistics Admitted Patient Care data andmortality data from
the Office for National Statistics. Scientific approval for this
studywas given by theCPRD independent scientific advisory
committee and, as an observational study using anonymized
data, was exempt from the requirement for patient consent.
Study Population
The studywas restricted to recordsof acceptable quality15 and
approved for Hospital Episodes Statistics and Office for
National Statistics linkage. Patients eligible for inclusion in
the studyweremen andwomen 16 years and older whowere
registered with their general practice for at least 12 months.
Wedefined incidentheart failureas the first recordofheart fail-
ure in primary care or hospital admission records from any
diagnostic position using a comprehensive set of diagnostic
codes (eTable 2 in the Supplement) and following previously
publishedmethods.16 For those who received their diagnosis
in thehospital, the date of diagnosiswas set to thedate of dis-
charge.We identifiedall incidentheart failure cases fromJanu-
ary 1, 2002, to December 31, 2013, and excluded individuals
whose first diagnosis referred to a preexisting condition
(eTable 3 in the Supplement) orwas recordedbefore the study
start date (January 1, 2002) or within the first 12 months of
registration with the general practice.
Study Outcomes
We investigated mortality rates at 1 year following incident
diagnosis as well as the number of hospital admissions with
anovernight staywithin 1yearof incidentdiagnosis (notcount-
ing index admission for those who received their diagnosis
in the hospital). The cause of death was defined as the first
reported cause in each patient’s death certificate. The cause
of hospitalization was defined as the primary discharge diag-
nosis. Causes of death and hospitalization were mapped to 9
and 11 disease categories, respectively (eAppendix 1 in the
Supplement). In subgroup analyses, disease categories were
further grouped into cardiovascular and noncardiovascular
causes (eTable 4 in the Supplement).
Baseline Variables
Weextractedbaselinecharacteristics frompatients’health rec-
ords, including socioeconomic status, systolic and diastolic
blood pressure, smoking status, bodymass index (calculated
as weight in kilograms divided by height in meters squared),
and the prevalence of 17 comorbidities (eAppendix 2 in the
Supplement). Baseline characteristics are presented as fre-
quencies (percentage) for categorical data, medians and in-
terquartile ranges for non-normally distributed continuous
data, or mean (SD) for normally distributed continuous data.
Key Points
Question Why has there been no improvement in the prognosis
for patients with heart failure over the past 15 years when
considerable advances in heart failure care have been introduced
during the same period?
Findings In this cohort study of patients who received a new
diagnosis of heart failure between 2002 and 2013 in the United
Kingdom, cardiovascular mortality declined by 27% and
premature deaths from any cause declined by 21%. Improvements
to overall mortality were hindered by noncardiovascular diseases,
which representedmost deaths and increased by 22% over time.
Meaning Management strategies that solely target cardiovascular
outcomes appear insufficient to improve the survival of patients
with heart failure; the management of associated comorbidities,
particularly infection prevention, appears as a major priority and
opportunity.
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Statistical Analysis
We report crude mortality and hospitalization rates as well
as adjusted rate ratios (RRs) by calendar year of diagnosis
and subgroups (age, sex, socioeconomic status, and place of
diagnosis). Crude mortality rates were computed as the
cumulative incidence of mortality at 1 year accounting for
observation time. Cause-specific mortality rates were com-
puted accounting for the competing risk of death from other
causes.17 Hospitalizations were assessed as the number of
hospital admissions per patient-years of follow-up within
1 year of heart failure diagnosis.
To examine trends over time and by subgroup, we used
Poisson regression models offset for observation time and
present resulting rate ratios and corresponding 95% confi-
dence intervals. All models account for the calendar year of
diagnosis, age at diagnosis (as a continuous variable), sex,
region, socioeconomic status, and baseline comorbidities.
Follow-up timewas considered fromthedateof incidentheart
failure diagnosis up to the earliest of the following dates:
patient died, patient deregistered from their practice, or the
practice ceasedcontributingdata, and foramaximumof 1year.
To assess the robustness of observed temporal trends,we
grouped the first 3 and the last 3 years of the study together
and assessed whether the direction and statistical signifi-
cance of trends were similar to those reported in the main
analyses. The study findings are reported in accordance with
the Reporting of Studies Conducted Using Observational
Routinely Collected Health Data recommendations.18 Statis-
tical analyses were performed in R, version 3.4.2 (R Founda-
tion) and statistical significance was set at P< .05.
Results
We identified 86833 patients who developed incident heart
failure from 2002 to 2013. At the time of diagnosis, 41 88
patients (48%) were 80 years or older, 42 581 (49.0%) were
women, and 68451 (79%) had 3 or more comorbidities. Over
the study period, we observed amodest increase in patients’
age at diagnosis, a marked increase in multimorbidity, and a
greater proportion of patients who received diagnoses in
secondary care settings as opposed to primary care (Table).
Mortality
One-yearmortality rates following incident heart failurewere
high (32%)anddeclinedonlymodestlyover theperiodof study
(adjusted RR comparing 2013 with 2002, 0.94; 95% CI, 0.88-
1.00).When overall mortality rateswere stratified by specific
causes, diverging trends between death from cardiovascular
andnoncardiovascularcausesbecameapparent.One-yearmor-
tality rates from cardiovascular causes declined from 18% in
2002 to 13% in 2013 (RR 2013 vs 2002, 0.73; 95% CI, 0.67-
0.80), whereas noncardiovascular mortality rates increased
over the sameperiod from 13% to 17% (RR 2013 vs 2002, 1.22;
95%CI, 1.11-1.33). Among patientswho died in 2013, themost
frequent causes of death after cardiovascular diseases (43%of
alldeaths)wereneoplasms (15%), infections (13%), andchronic
respiratory conditions (12%). Deaths associated with infec-
tions, chronic respiratorydiseases, injuries, andmental health
orneurological disorders increasedduring theperiodof study
(Figure 1). Mortality due to infections accounted for the larg-
est absolute increase over time, representing 173 (8%) and279
(13%)deaths in2002and2013, respectively (RR2013vs 2002,
1.60; 95%CI, 1.31-1.95). Further analyses of individual causes
of death revealed influenza and pneumonia as important and
increasing causes of death (1915deaths [6%] at 1 year; RR2013
vs 2002, 1.59; 95%CI, 1.26-1.99), nowaccounting for about as
many deaths as myocardial infarction and more deaths than
cerebrovascular disease. Although mortality from chronic
respiratorydiseaseswas largelydue tochronicobstructivepul-
monary disease, the increase over time in this category was
attributable to interstitial lungdiseases,which represented 13
(1%)and37 (2%)deaths in2002and2013, respectively (RR2013
vs 2002, 3.37; 95% CI, 1.77-6.42). Finally, deaths from inju-
ries were most commonly associated with falls or unspeci-
fied incidental causes and deaths attributed tomental health
and neurological disorders were largely due to dementia,
including Alzheimer disease (eTable 5 in the Supplement).
Age-stratified analyses further revealed diverging trends
over time:all-causemortalitydeclinedamongpatientsyounger
than 80 years (RR 2013 vs 2002, 0.79; 95% CI, 0.71-0.88) but
not in older individuals (RR 2013 vs 2002, 0.97; 95% CI, 0.9-
1.06).Cause-specificanalysesshowedthatcardiovascularmor-
tality declined across all age groups, although less steeply in
older age groups, and that the increase in noncardiovascular
mortalitywas largelyattributable toolderagegroups (Figure2).
Individual causes of death also differed by age. Specifically,
digestive diseases (in particular liver cirrhosis) and neo-
plasms were more common in younger patients, whereas in-
fectionsandmentalhealthorneurologicaldisordersweremore
common in older age groups (eFigure 1 in the Supplement).
While overall mortality was similar in men and women
(Figure 3), causes of death presented sex-specific patterns.
Differenceswereparticularlyapparentamongpatientsyounger
than 65 years regarding cardiovascular causes (more promi-
nent in men), cancer, and infections (more prominent in
women) (eFigure 1 in the Supplement).
Finally, patients’ socioeconomic backgroundand the care
setting in which patients first received their diagnoses were
importantpredictorsofhealthoutcomes.For the sameageand
sex, patients from more deprived socioeconomic back-
groundshad 19%highermortality rates than theirmore afflu-
ent counterparts (RR formostdeprivedvs least deprivedquin-
tile, 1.19; 95% CI, 1.15-1.24; Figure 3). One-year mortality was
also higher in patients who received their heart failure diag-
nosis in the hospital (19 167 [41%]) compared with those re-
ceiving their diagnosis in primary care (8231 [22%]) (RR for
hospital vs primary care diagnoses, 2.29; 95% CI, 2.23-2.35;
Figure 3). Among those who received their diagnosis in the
hospital, 10 302 (21%)diedbefore discharge, and rates didnot
change significantly over the study period (RR 2013 vs 2002,
0.91; 95% CI, 0.82-1.01).
Hospitalizations
The number of hospital admissions in the year following
incident heart failure was high (1.15 hospitalizations per
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Table. Baseline Characteristics of PatientsWith Incident Heart Failure in CPRD From 2002 to 2013a
Characteristic
No. (%)
Full Cohort
(N = 86 833)
Period
2002-2004
(n = 21 943 [25%])
2011-2013
(n = 22 065 [25%])
Age, mean (SD), y 76.6 (12.6) 76.5 (12.1) 76.9 (12.9)
Age ≥ 80 y 41 888 (48) 10 129 (46) 11 079 (50)
Women 42 581 (49) 10 889 (50) 10 718 (49)
Race/ethnicity
White 51 215 (88) 12 038 (92) 16 219 (87)
Missing 28 316 (33) 8912 (41) 3431 (16)
Socioeconomic status
1 (Least deprived) 17 024 (20) 4177 (19) 4514 (20)
2 18 680 (22) 4680 (21) 4808 (22)
3 18 709 (22) 4769 (22) 4734 (21)
4 17 149 (20) 4387 (20) 4230 (19)
5 (Most deprived) 15 271 (18) 3930 (18) 3779 (17)
Systolic blood pressure
Mean (SD), mm Hg 133 (21) 137 (24) 130 (19)
Missing 5080 (6) 2601 (12) 682 (3)
Diastolic blood pressure
Mean (SD), mm Hg 75 (11) 77 (12) 73 (11)
Missing 5192 (6) 2601 (12) 705 (3)
BMIb category
Underweight 2022 (4) 329 (3) 611 (4)
Normal 16 090 (31) 3000 (31) 4632 (31)
Overweight 17 397 (34) 3434 (35) 4889 (32)
Obesity 9742 (19) 1824 (19) 2872 (19)
Severe obesity 6440 (12) 1086 (11) 2080 (14)
Missing 35 142 (40) 12 270 (56) 6981 (32)
Smoking
No 27 405 (41) 5081 (41) 7377 (41)
Former 30 191 (45) 5192 (42) 8416 (46)
Yes 9002 (14) 2031 (17) 2320 (13)
Missing 20 235 (23) 9639 (44) 3952 (18)
Diagnosis setting
Primary care 38 448 (44) 11 952 (54) 8266 (37)
Hospital admission, HF primary cause 10 838 (12) 2650 (12) 2588 (12)
Hospital admission, HF secondary cause 37 547 (43) 7341 (33) 11 211 (51)
Cardiovascular comorbidities
Atrial fibrillation 34 048 (39) 6990 (32) 9884 (45)
Hypertension 57 639 (66) 11 938 (54) 16 540 (75)
Ischemic heart disease 42 513 (49) 10 279 (47) 11 032 (50)
Peripheral artery disease 12 562 (14) 2754 (13) 3432 (16)
Stroke 16 186 (19) 3893 (18) 4389 (20)
Respiratory comorbidities
Asthma 20 119 (23) 4366 (20) 5867 (27)
Chronic obstructive pulmonary disease 16 560 (19) 3782 (17) 4720 (21)
Other comorbidities
Anemia 22 277 (26) 4187 (19) 6987 (32)
Cancer 21 512 (25) 4360 (20) 6466 (29)
Chronic kidney disease 20 526 (24) 1370 (6) 7940 (36)
Dementia 5203 (6) 1003 (5) 1689 (8)
Depression 18 663 (21) 3963 (18) 5507 (25)
(continued)
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patient-year at risk). Although crude rates increased by 20%
over time, adjusted rates accounting for patient characteris-
tics and comorbidities at baseline declined by 6% over the
study period (RR 2013 vs 2002, 0.94; 95% CI, 0.90-0.98;
Figure 4).
Admissions for heart failure represented 13% of hospital-
izations within a year of diagnosis (0.14 hospitalizations per
patient-year at risk) and showed a relative decline of 11% over
the study period (RR 2013 vs 2002, 0.89; 95%CI, 0.80-0.99).
Overall, hospitalizations associated with any cardiovascular
Table. Baseline Characteristics of PatientsWith Incident Heart Failure in CPRD From 2002 to 2013a (continued)
Characteristic
No. (%)
Full Cohort
(N = 86 833)
Period
2002-2004
(n = 21 943 [25%])
2011-2013
(n = 22 065 [25%])
Diabetes 18 847 (22) 3893 (18) 5465 (25)
Dyslipidemia 23 486 (27) 3360 (15) 8253 (37)
Obesity 10 729 (12) 1659 (8) 3772 (17)
Osteoarthritis 37 039 (43) 7960 (36) 10 702 (49)
Thyroid disorder 10 401 (12) 2099 (10) 3027 (14)
Three or more comorbidities 68 451 (79) 14 876 (68) 19 018 (86)
Abbreviations: BMI, bodymass index; CPRD, Clinical Practice Research Datalink; HF, heart failure.
a Number and percentage of records with missing data are displayed for variables with missing entries. Category
percentages refer to complete cases. Socioeconomic status refers to Index of Multiple Deprivation 2015 quintile,
with 1 referring to themost affluent and 5 to themost deprived quintile. Number of comorbidities refers to any
of the 17 conditions investigated.
bCalculated as weight in kilograms divided by height in meters squared.
Figure 1. Temporal Trends in All-Cause and Cause-Specific Mortality Rates
at 1 Year Following Incident Heart Failure
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Adjusted trends with rate ratios comparing 2013 with 2002B
Injuries 3.35 (1.78-5.92)
Kidney diseases 0.33 (0.19-0.55)
Digestive diseases 1.19 (0.87-1.63)
Mental health and neurological disorders 2.14 (1.44-3.18)
Chronic respiratory diseases 1.23 (1.01-1.48)
Infections 1.60 (1.31-1.95)
Neoplasms 0.88 (0.74-1.03)
Cardiovascular diseases 0.73 (0.68-0.80)
Any cause 0.94 (0.88-1.00)
Other
Injuries
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Mental health and
neurological disorders
Chronic respiratory diseases 
Infections
Neoplasms
Cardiovascular diseases
Other 1.14 (0.83-1.57)
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RR (95% CI)
A, Crude rates of all-cause and
cause-specific mortality at 1 year
following incident heart failure
diagnosis. Labels for years 2002 and
2013 present individual causes of
death as a share of the total number
of deaths at 1 year. B, Rate ratios
(RRs) frommultivariable Poisson
regressionmodels comparing 1-year
mortality rates in 2013 with 2002 by
first reported cause, adjusting for
patients’ age, sex, socioeconomic
status, region, and 17 baseline
comorbidities.
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reason (eg, heart failure or another cardiovascular disorder)
represented fewer than half of all admissions and did not
change significantly over time (0.46 hospitalizations per pa-
tient-year at risk; RR 2013 vs 2002, 0.96; 95% CI, 0.91-1.03).
In parallel, admissions for some noncardiovascular causes,
in particular infections and injuries, increased (Figure 4).
Age-stratified patterns of hospital admissions were simi-
lar to those reported formortality. The number of admissions
declined among patients younger than 80 years (RR 2013 vs
2002, 0.82; 95% CI, 0.77-0.88) but not in older individuals
(RR 2013 vs 2002, 1.12; 95%CI, 1.04-1.21). Differences by sex,
socioeconomic status, and place of diagnosis were also con-
sistent, although less pronounced than those reported for
mortality (eFigures 2 and 3 in the Supplement).
Discussion
This study reveals possible explanations for the standstill in
mortality observed among patients with heart failure
in many high-income countries. Important improvements in
cardiovascular mortality have been offset by a large and
increasing number of deaths due to noncardiovascular disor-
ders, such as infections and respiratory problems. Overall
survival rates improved in younger and middle-aged
patients as a result of fewer cardiovascular deaths, yet mor-
tality changed little in patients 80 years or older who com-
prised almost half of all heart failure cases. Broadly similar
findings were seen for hospital admissions.
The temporal trends in all-cause mortality rates ob-
served in this study align with earlier reports from high-
income countries that have also shown little change since the
mid-2000s (eTable 1 in theSupplement).Previousstudieshave
rarely investigated underlying causes of death or hospitaliza-
tions and had limited ability to adjust for other concomitant
changes, such as the rise in comorbidities over time. To our
knowledge, the only study that has reported cardiovascular
and noncardiovascular mortality andmorbidity trends sepa-
rately was the Olmsted county study, which was limited by
sample size and statistical power tomake robust conclusions
about changing patterns.12 Complementing these earlier
studies,we found thatwithin the last 12 years, the relative risk
of death from cardiovascular causes after incident diagnosis
of heart failure has declined by 27%.However, this important
improvement in outcomes was offset by a 22% increase in
noncardiovascular death rates. While the increasing burden
of multimorbidity in patients with heart failure may have
contributed to the observed changes in causes of death, our
analyses show that the increase in noncardiovascular events
remains significant after adjusting for 17 major comorbidi-
ties, and hence suggest that other factors contribute.
Current heart failure treatment is intrinsically disease-
centered and essentially focused on cardiac dysfunction and
its consequences.Cardiovascularmortality andadmissions for
heart failurearekey indicatorsof theeffectivenessofheart fail-
ure–specific treatments. Thus, the decline in cardiovascular
events is encouraging and appears to follow the introduction
of national reporting and incentives schemes to improve
evidence-based heart failuremanagement19,20 and increased
use of life-saving therapies, which have been observed dur-
ing the study period.9 However, this study also revealed that
noncardiovascularoutcomesnowaccount formostdeathsand
hospitalizations, a finding that is consistent with studies of
unselected patient populations12,14 but represents a much
higher sharecomparedwith reports fromclinical trials.21These
findings challenge current research priorities and manage-
ment strategies and have implications for the development
of life-saving therapies.
Noncardiovascular comorbidities, hospitalizations, and
deaths are in themselves an important potential therapeutic
target in patients with heart failure. For example, infections
appeared to represent the largest driver behind the recent in-
crease innoncardiovascularmortality andhospitalizationswe
observed in this study.Most infection-associateddeathswere
due to influenza andpneumonia and someof thosemayhave
been preventable through better care. For instance, the cov-
erage of influenza vaccination amongpatientswithheart fail-
ure in theUnitedKingdom,althoughhighcomparedwithmany
Figure 2. Temporal Trends in All-Cause and Cause-Specific Mortality Rates
at 1 Year Following Incident Heart Failure by Age Group
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Figure 3. Differences inMortality Rates 1 Year After Incident Heart Failure (HF) by Sex, Socioeconomic Status, and Diagnosis Care Setting
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2 15 1.02 (0.97-1.08)
5 (Most deprived)
15 1.02 (0.97-1.08)
4 16 1.13 (1.07-1.20)
16 1.18 (1.11-1.25)
Diagnosis setting
Primary care 8 1 [Reference]
Hospital admission, HF primary cause 15 2.33 (2.19-2.48)
Hospital admission, HF secondary cause 23 3.61 (3.46-3.77)
Noncardiovascular mortalityC
0.75 1.00 1.50
Adjusted RR (95% CI)
1.500.75
Adjusted RR (95% CI)
1.50
2.00
2.00
1.00
1.00
2.50
2.500.75
4.002.00 2.50
4.00
4.00
Adjusted RR (95% CI)
Crudemortality rates by subgroups alongside rate ratios (RRs) and 95%
confidence intervals frommultivariable Poisson regressionmodels accounting
for year of diagnosis, age (as a continuous variable), sex, socioeconomic status,
region, and 17 baseline comorbidities. Socioeconomic status refers to Index of
Multiple Deprivation 2015 quintile, with 1 referring to themost affluent and
5 to themost deprived socioeconomic quintile.
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other countries,22 has been declining,23 which could have
contributed to the observed trend.
Chronic respiratory conditions, injuries, and dementia
further contributed to the increasing rates of noncardiovas-
cular mortality, yet with a more modest association with
overall burden. The observed increase in mortality from
chronic respiratory conditions was largely attributable to
interstitial lung diseases. This finding is consistent with
reports of increasing rates of detection, incidence, and mor-
tality associated with interstitial lung diseases in the general
population, in the United Kingdom, and worldwide24-26 and
may, therefore, not be specific to heart failure. Nonetheless,
patients with heart failure often receive treatments known to
cause pulmonary fibrosis, including antibiotics, amiodarone,
and repeated exposure to therapeutic oxygen.27,28 Further
studies are needed to fully understand the reasons for the
increasing rates of interstitial lung diseases among patients
with heart failure and guide clinical decision-making in
patients at high risk of pulmonary complications.
Falls are common in elderly populations29 and the per-
ception that the blood pressure–lowering effects of heart fail-
ure therapies may place patients at even higher risk some-
timescreatesabarrier toeffectively treatingpatientswithheart
failure in the community.30,31 This study quantifies the long-
termassociationof injurieswithpatientswithheart failureover
a period of time that has witnessed a gradual increase in the
useofbloodpressure–loweringtherapies9andshowsthatwhile
rates of injuries in this cohort have increased over time, their
contribution tooverallmortalityandmorbidity inpatientswith
heart failure remains relativelymodest (2% of deaths and 7%
of hospitalizations are associated with injuries). Hence these
findingsdonot support theperception that falls present ama-
jor health burden among patients with heart failure. Never-
theless, strategies to avoid falls andprevent injuries are an ap-
propriate focus in these patients, in particular in the context
of high rates of osteoporosis in this patient group.32
Our age-stratified analyses provide additional insights
into underlying mechanisms and opportunities to improve
Figure 4. Temporal Trends in All-Cause and Cause-Specific Mean Number of Hospitalizations at 1 Year Following Incident Heart Failure
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Increasing Over TimeCause
RR
(95% CI)
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Digestive diseases 0.85 (0.72-1.00)
Mental health and neurological disorders 0.86 (0.67-1.10)
Chronic respiratory diseases 0.99 (0.85-1.14)
Infections 2.13 (1.88-2.41)
Neoplasms 0.57 (0.47-0.68)
Other cardiovascular diseases 0.99 (0.92-1.07)
Heart failure 0.89 (0.89-0.99)
Any cause 0.94 (0.90-0.98)
Other
Musculoskeletal disorders
Injuries
Kidney diseases
Digestive diseases
Mental health and
neurological disorders
Chronic respiratory diseases
Infections
Neoplasms
Other 0.70 (0.64-0.77)
Musculoskeletal disorders 0.88 (0.71-1.10)
Injuries 1.22 (1.04-1.44)
Other cardiovascular diseases
Heart failure
0.25 0.50 1.00 1.50 2.00 3.00
RR (95% CI)
A, Crudemean number of hospitalizations within 1 year of incident heart failure
per patient-years at risk by primary discharge diagnosis. Labels displayed for
2002 and 2013 present individual discharge diagnoses as a share of the total
number of hospitalizations in the given year. B, Rate ratios (RRs) from
multivariable Poisson regressionmodels comparing mean number of
hospitalizations at 1 year in 2013 with 2002 offset for patient-years at risk by
primary discharge diagnosis, adjusting for age, sex, socioeconomic status,
region, and 17 baseline comorbidities.
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patient care. Declining rates of cardiovascular mortality
across all age groups show that progress in cardiovascular
care has benefitted young and old. However, unchanged sur-
vival among older patients highlights the importance of mul-
timorbidity, frailty, and senescence rather than cardiac dys-
function as important determinant of prognosis. With about
80% of patients with heart failure having multiple comor-
bidities and almost 50% being 80 years or older at the time
of diagnosis, it appears crucial to better understand the
needs of patients encountered in usual care and to reassess
research objectives and therapeutic options accordingly.
Strengths and Limitations
A strength of this study is the large patient cohort studied,
providing sufficient cases for cause-specific analyses, and the
long period of study, which allowed study of long-term
trends. This population-based cohort also reflects patients as
encountered in routine care so that findings are likely to be
more broadly generalizable compared with surveys or clinical
trials that enroll selected participants. One of the key limita-
tions of this study was the relatively limited clinical informa-
tion contained in electronic health records. In particular, left
ventricular ejection fraction measurements were not avail-
able and we were unable to stratify analyses by type of heart
failure. While this limitation is important, particularly as
heart failure treatments have only been demonstrated to be
effective in patients with heart failure and reduced ejection
fraction, evidence from several large-scale observational
studies shows that mortality rates and trends over time do
not differ significantly between patients with preserved or
reduced ejection fraction.12,33 Moreover, the current evidence
base does not suggest that the case-mix of patients with
newly diagnosed heart failure would have shifted signifi-
cantly toward one or the other type of ejection fraction over
the study period.12 Another limitation of this study is that we
are unable tomake any direct inference on the actual associa-
tion of adherence with guideline-recommended medical
treatment toward the observed temporal changes in deaths
and hospitalizations. Further limitations arise from to the
limited information available to adjust for disease severity at
baseline or the clinician (eg, specialty of admission ward).
Finally, research using routinely collected health care data
also rely on the accuracy of clinical coding input. The validity
of clinical diagnoses recorded in UK primary care, secondary
care, and death certificates CPRD has been independently
investigated for a range of conditions and is generally consid-
ered appropriate for the purpose of this study (eAppendix 3-5
in the Supplement).
Conclusions
Our findings have important implications for public health
policies. Significant reductions in cardiovascular events and
improved survival of patients with heart failure patients
younger than 80 years attest to the progress made in patient
care and encourage continued efforts to increase the use of
evidence-based therapy. Further improvements in patient
prognosis are likely to require a broader perspective on heart
failure management, one that considers not only patients’
cardiovascular health but also the range of associated comor-
bidities and special needs of elderly patients.
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